University of Pennsylvania Medical Center — Philadelphia, Pennsylvania

University of Pennsylvania Medical Center is a clinical research site located in Philadelphia, Pennsylvania, United States 19104-6149.

Crixeo Clinical Trials Trust Score: 93/100 (GOOD). This profile has not yet been claimed by the site owner.

University of Pennsylvania Medical Center has participated in 61 clinical trials with 11 currently active.

Therapeutic areas: Cushing Disease, Epithelial Ovarian Cancer, Fallopian Tube Cancer.

Sponsors: Novartis Pharmaceuticals, Celgene, Wake Forest University Health Sciences.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Philadelphia

Browse all research sites in Pennsylvania · View every site in Philadelphia

Sponsor Feasibility Report

Trust Score: 93/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Pennsylvania Medical Center?

University of Pennsylvania Medical Center has a Crixeo Trust Score of 93/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Pennsylvania Medical Center conducted?

University of Pennsylvania Medical Center has 61 clinical trials on record, with 11 currently active. Their work covers Cushing Disease, Epithelial Ovarian Cancer, Fallopian Tube Cancer.

Is University of Pennsylvania Medical Center accredited by Crixeo Clinical Trials?

University of Pennsylvania Medical Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Pennsylvania Medical Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.